partnering360 is part of the KNect365 of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Companies to watch: Biotech startups get trendy
John Carroll ENDPOINTS

John Carroll, Editor and Co-founder of Endpoints

Over the past few years we’ve seen a remarkable swell in the amount of money that’s been coursing through the biotech industry. Last year the US and other hubs racked up record amounts of venture cash being injected into startups as the IPO boom reached a crescendo. And even after the market swooned, we’re still seeing a steady stream of life science companies lining up to go public while venture investing continues at only a slightly slower pace.


For biotech’s top hubs—places like Boston/Cambridge, the Bay Area, and the Golden Triangle in the UK—there’s never been a better time to line up funding and tackle a new drug. And some new regions, like New York and Shanghai, are making a serious bid to join the list of emerging hubs. Experienced teams, some led by serial entrepreneurs or the execs leaving big pharma and biotech, can be recruited and fielded in a matter of months. (more…)

Share Button
Relationship-centric care: The power of digital health to transform and improve clinical trials

Digital Medicine Connect 2016

We have all pondered the million-dollar question: In what way can healthcare and digital technology converge that will bring about lasting, clinically and economically impactful change to the effectiveness of therapeutics?


The answer might not lie exclusively in the physician-to-patient realm. Digital health applications have the power to not only improve monitoring between routine checkups, but also help us reimagine a much earlier phase in the healthcare innovation pipeline: clinical trials. (more…)

Share Button
Industry experts weigh in on Brexit situation and implications for the life science sector


partnering360® recently spoke with Alasdair Stamps, Chairman of the Advisory Board and co-Founder of BioPartner UK, and Dr. Claire Skentelbery, Network Manager of Council of European BioRegions and researcher for Scientists for EU, to get their opinions on Brexit and its potential effects on life science collaborations in the EU. BioPartner UK is an independent, accredited trade organization that promotes international partnering for trade, investment and collaborations with UK life science companies. Council of European BioRegions (CEBR) is a network of clusters across Europe, while Scientists for EU is a group campaigning for UK science during the referendum, with over 136,000 members.


Share Button
Single-use technology means big cost savings for bioprocessing industry


What does adoption of single-use technology mean for the bioprocessing industry?


The R&D and manufacturing of biologics and biosimilars is extremely expensive due to the amount of detail necessary to replicate and ensure validation of biosynthesis of living cells and their components. It can take an average of 10 years and USD 2.7 billion per drug, according to Wolfgang Kuhne, VP, Technical Development Bioprocessing and Clinical Supply at Roche Diagnostics, as quoted in a recent blog post on Knect365 Bioprocessing blog. The post, entitled, “Single-use technology: The future of the bioprocessing industry?”, gives additional perspectives from leading industry figures, or see a featured infographic on the benefits of single-use technologies. (more…)

Share Button
Promise of genome and cell therapies move closer to reality

partnerships-in-cell-and-gene-therapies-biopharm-americaStem cell technologies and adoptive immunotherapies are big buzzwords in the cell therapies world, with the promise of personalized therapies driving interest. Boston is a hotbed for cell and gene therapies potential. STATnews reported today that “several Boston-area hospitals have teamed up with the Harvard Stem Cell Institute and biotech Semma Therapeutics to make personalized cell-based therapies and organize clinical trials.” (more…)

Share Button
Surviving as a CMO

Pharmaceutical Manufacturing Technologist


What are the key factors for survival as a CMO today? Nordic Life Science has spoken to some Nordic CMOs to get an insight into the current possibilities and challenges.

Guest post by Anneli Hidalgo, Nordic Life Science


The pharmaceutical sector is undergoing some dramatic changes, with pipeline challenges, pricing pressures and emerging global markets reshaping the way that companies operate. The CMO marketplace has not been spared and has become a brutally competitive one. For smaller US and European CMOs competing with Indian and Chinese CMOs the solution may ultimately be to merge with each other or abandon particular specialties within pharmaceutical manufacturing. Another alternative is to quit the business completely in order to survive, according to the article The Future of Pharmaceutical Contract Manufacturing by Robin Elizabeth Margolis. (more…)

Share Button
Entrepreneurship, community and serious tax incentives combine to make Puerto Rico an ideal life science hub


If you want a lesson in the opportunities available in Puerto Rico, talk to Ignacio Pino. Pino’s company, CDI Laboratories, Inc., a CRO located in Guanajibo Research and Innovation Park in Puerto Rico, is focused on advanced proteomics. “We are a hybrid CRO as we also call ourselves content developers in relation to developing tools that accelerate human protein research, specifically high-content protein microarrays, and highly specific monoclonal antibodies. Protein research is important to understand diseases like cancer and autoimmune disorders.” CDI creates unique tools and services to accelerate research in these areas, and also commercializes these tools for those who adopt the technology to use them internally, in their labs.



Share Button
How drug development is like your diet


If you’re like me, you read the dailies. Companies run the gamut from riding high and plump on investment infusion to rock hard abs times when they’re all muscle and no fat, and, possibly back again. With summer coming, it occurred to me that drug development cycles are very much like dieting, and the lessons learned at each phase are strikingly similar. (more…)

Share Button
From Zika virus to fast, high quality clinical trials: Puerto Rico’s Consortium for Clinical Investigation (PRCCI)

Biolatam® 2016

Situated just 1,200 miles from the mainland US, a hotspot of clinical trial activity is being established on a small island paradise. If you haven’t heard of the Puerto Rico Consortium for Clinical Investigation (PRCCI), you should. What this organization is doing in clinical research trials for international drug development companies is huge.


The PRCCI is a not-for-profit consortium of high-quality research sites invested in increasing the speed and quality of clinical trials. To put that into context, the PRCCI acts as the single point of contact for sponsor organizations, mainly pharma companies and CROs, to connect with pre-qualified research sites and clinical investigators, thus ensuring the quality of the clinical trial overall. According to Kosmas Kretsos, PhD, MBA, Executive Director of PRCCI, “The PRCCI makes life easier for sponsors, in that they can rely on high quality standards for their clinical trials enforced for each and every clinical trials unit (CTU) in this consortium.” (more…)

Share Button
Digital Health: Still a brave new world

Digital Medicine Connect

At this year’s BIO-Europe Spring® panel on “The Convergence of Therapeutics and Digital Health,” two panelists from big pharma joined two from Scandinavian digital health companies, agreeing that while the platform for digital health technologies is strong in Europe, much trailblazing remains to be done to clarify the complexities in regulation and adoption of new roles within the digital health sphere.


“Digital is coming to all industries. And even the most regulated, like banking, have been revolutionized by it,” said panel moderator Erika Rask of MedUniverse, a patient case software and web service for healthcare professionals. Indeed there is no doubt that as patients demand more direct treatment information and healthcare providers call for lower drug costs, business models must adapt. In the words of Nima Jokilaakso, Executive Partner at digital health consultancy D Health Scandinavia, “The healthcare ecosystem is being completely reshaped around pharma, technology developers and new players.”


Share Button